# US 2019/0314338 A1 · Use Of Carbamate Compound For Prevention, Alleviation, Or Treatment Of Demyelinating Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314338 A1
- Document ID: US20190314338A1
- Status: Published application
- Kind: A1
- Application number: 16/468,985
- Filed: 2017-12-14
- Published: 2019-10-17
- Earliest claimed: 2016-12-14
- Assignees: SK Biopharmaceuticals Co., Ltd.
- Applicants: SK Biopharmaceuticals Co., Ltd.
- Inventors: Sun Gwan HWANG; Jihye KIM; Jimok YOON
- Web page: https://patentgrep.com/patent/US20190314338A1

## CPC

- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a use for preventing, alleviating or treating a demyelinating disease by administering a pharmaceutical composition containing a carbamate compound of chemical formula 1.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method for preventing, alleviating or treating demyelinating diseases in a subject, comprising administering to the subject a therapeutically effective amount of a carbamate compound of the following Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof:
wherein,
R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy and C1-C8 alkoxy; and
one of A1 and A2 is CH, and the other is N.

### Claim 20 (depends on 19)

The method according to claim 19, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen and C1-C8 alkyl.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the carbamate compound of Formula 1 is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester of the following Formula 2:

### Claim 22 (depends on 19)

The method according to claim 19, wherein the demyelinating diseases are one or more selected from the group consisting of Multiple sclerosis, Devic's disease, Inflammatory demyelinating diseases, Central pontine myelinolysis, Tabes dorsalis, Leukoencephalopathies, Leukodystrophies, Optic neuritis, Transverse myelitis, Guillain-Barré syndrome, Chronic inflammatory demyelinating polyneuropathy, Anti-MAG peripheral neuropathy, Charcot-Marie-Tooth disease and Progressive inflammatory neuropathy.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the method is for the prevention, alleviation or treatment of multiple sclerosis.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the multiple sclerosis is one or more selected from the group consisting of Clinically isolated syndrome (CIS), Radiologically isolated syndrome (RIS), Clinically definite multiple sclerosis (CDMS), Relapsing remitting multiple sclerosis (RR-MS), Secondary progressive multiple sclerosis (SP-MS), Primary progressive multiple sclerosis (PP-MS) and Progressive relapsing multiple sclerosis (PR-MS).

### Claim 25 (depends on 22)

The method according to claim 22, wherein the method is for the prevention, alleviation or treatment of optic neuritis.

### Claim 26 (depends on 19)

The method according to claim 19, wherein the subject is a mammal.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the mammal is a human.

### Claim 28 (depends on 19)

The method according to claim 19, wherein the therapeutically effective amount of the carbamate compound of Formula 1 is 50 mg to 500 mg based on the free form.

### Claim at position 12

29-36. (canceled)
